Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

The primary objective of this protocol is to collect the 2-dimensional (2D) screening and diagnostic images, and 3-dimensional (3D) Digital Breast Tomosynthesis (DBT) scans from patient mammography examinations acquired on various commercially available Full Field Digital Mammography (FFDM) systems and the Siemens Inspiration DBT system, respectively.

Key facts

Study ID

NCT01373671

Run by

Siemens Medical Solutions USA - CSG

People needed

764

Starts

2011-05-01

Expected to finish

2014-05-01

Last updated by the study team

2020-08-07

Who can join

Age: 30 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• All subjects enrolled into the collection study must:
• Provide signed informed consent after receiving a verbal and written explanation of the purpose and nature of the study
• be females, 40 years of age or older at the screening mammographic evaluation or age 30 or older presenting for a biopsy and have one of the following mammograms:
• o Normal cases at screening (BI-RADS® 1, 2 and 3):
• have a screening mammogram that includes the four standard screening views (RCC, RMLO, LCC and LMLO), as well as have both MLO and CC DBT scans of each breast,
• o Actionable cases at screening (BI-RADS® 0, 4 or 5) with final BI-RADS® 1, 2, 3, 4 or 5:
• have a screening mammogram with four SSVs and any clinically necessary diagnostic mammographic views, such as straight lateral projections, rolled, magnification view and spot compression views, and, both MLO and CC DBT scans of each breast plus 4 SSVs repeated at the diagnostic or biopsy visit if the screening images are unavailable or were acquired more than 45 days prior to DBT acquisition,
• have supporting ground-truth documentation for the final BI-RADS® assessment as follows:
• A one (1) year FFDM follow up without evidence of cancer for normal cases not undergoing biopsy
• A six (6) or twelve (12) month FFDM follow up confirming benign status for biopsy proven benign cases
• Pathology report for either benign or malignant biopsy finding

You may not qualify if…

• Subjects with any of the following conditions or who have had the following procedures will be excluded from this study:
• Pregnant women or women who believe they may be pregnant or are trying to become pregnant.
• Mastectomy patients
• Subjects who have had lumpectomy ≤ 5 years prior to the study entry
• Inmates (in accordance with 45 CFR 46.306) or mentally disabled individuals
• BI-RADS® Category 6 (e.g., for which the mammogram was performed for the purpose of planning cancer therapy)
• BI-RADS® Category 4 or 5 without confirming pathology reports will be considered incomplete
• Subjects with mammograms that lack the required views or with views judged to be technically inadequate will be considered incomplete and the cases will not be considered for the MRMC reader studies
• Subjects being accrued from the screening population who know that they will not be in the United States or available for follow up mammograms in one year.

Where it is running

• Siemens Medical Solutions — Malvern, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.